期刊文献+

注射用紫杉醇脂质体二线治疗晚期胃癌的临床研究 被引量:1

原文传递
导出
摘要 目的评价注射用紫杉醇脂质体二线化疗晚期胃癌的疗效及不良反应。方法36例接受一线化疗后的晚期胃癌,使用注射用紫杉醇脂质体175mg/m^2,静脉滴注3h,每21天为1周期。所有患者完成2周期化疗后评价疗效。结果有效率(RR)19.4%,其中部份缓解(PR)7例,疾病稳定(sD)19例,疾病进展(PD)10例。中位无进展生存期为2.9个月,中位生存时间为6个月。不良反应主要为恶心、呕吐11.1%、乏力13.9%、神经麻木11.1%和粒细胞下降19.4%。主要为Ⅰ、Ⅱ级不良反应,对症处理均能缓解。结论注射用紫杉醇脂质体二线治疗晚期胃癌的疗效好,不良反应不严重。
出处 《中国综合临床》 2011年第5期521-522,共2页 Clinical Medicine of China
  • 相关文献

参考文献7

  • 1Duffaud F,Therasse P.New guidelines to evaluate the response to treatment in solid tumors[J].Bull Cancer,2000,87(12):881-886.
  • 2Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
  • 3Catalano V,Graziano F,Santini D,et al.Second-line chemotherapy for patients with advanced gastric cancer:who may benefit[J].Br J Cancer,2008,99(9):1402-1407.
  • 4Chau I,Norman AR,Cunningham D,et al.Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter,randomized,controlled trials using individual patient data[J].J Clin Oncol,2004,22(12):2395-2403.
  • 5Van Cutsem E,Moiseyenko VM,Tjulandin S,et al.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group[J].J Clin Oncol,2006,24(31):4991-4997.
  • 6吕雅蕾,刘巍.脂质体制剂用于恶性肿瘤靶向治疗的研究进展[J].临床荟萃,2003,18(23):1376-1377. 被引量:5
  • 7吴芳红.紫杉醇治疗肺癌的不良反应分析[J].中国医药,2010,5(5):433-434. 被引量:11

二级参考文献12

共引文献14

同被引文献12

  • 1徐瑞华,滕开原.晚期胃癌化疗进展[J].消化肿瘤杂志,2008,1(1):65-69.
  • 2Burstein HJ. Measuring hope:patient expectations of chemotherapyfor advanced cancer [ J]. J Natl Compr Cane Netw,2012,10(12):1459-1460.
  • 3Shimura T, Kitagawa M, Yamada T, et al. The impact of cross-resistance between paclitaxel and docetaxel for metastatic gastriccancer [J]. 0nkologie,2012,35(4) : 176-183.
  • 4Hill BT, Whelan RD, Shellard SA, et al. Differential cytotoxiceffects of docetaxel in a range of mammalian tumor cell lines andcertain drug resistant sublines in vitro [J]. Invest New Drugs,1994,12(3):169-182.
  • 5Einzig AI’Neuberg D,Remick SC,et al. Phase II trial of docetaxel(Taxotere ) in patients with adenocarcinoma of the uppergastrointestinal tract previously untreated with cytotoxicchemotherapy : the Eastern Cooperative Oncology Group ( ECOG)results of protocol El293 [ J]. Med Oncol,1996,13(2) :87-93.
  • 6Mauer AM,Kraut EH,Krauss SA,et al. Phase II trial ofoxaliplatin,leucovorin and fluorouracil in patients with advancedcarcinoma of the esophagus [ J]. Ann Oncol,2005,16(8):1320-1325.
  • 7Hejna M,Raderer M,Zacherl J,et al. Phase II study of docetaxel incombination with oxaliplatin in patients with metastatic or locallyadvanced esophagogastric cancer previously untreated withchemotherapy for advanced disease : results of the Central EuropeanCooperative Oncology Group Study ESGAS. 1.2.001 [J].Anticancer Drugs,2008,19(5) :535-539.
  • 8陈小兵,罗素霞,高晓会,韩黎丽,李宁,邓文英,周孟强,索振河.多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较[J].中国综合临床,2009,25(7):689-691. 被引量:5
  • 9唐黎,申剑,武明花.奥沙利铂联合5氟尿嘧啶及亚叶酸钙治疗晚期胃癌的临床观察[J].中国综合临床,2010,26(6):635-637. 被引量:3
  • 10肖建新,郭贺,陈雷.多西他赛联合奥沙利铂治疗复治晚期食管癌的临床研究[J].中华肿瘤防治杂志,2011,18(3):216-218. 被引量:12

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部